KCAS Bio and Crux Biolabs Announce Global Spectral Flow Cytometry Alliance
May 03 2024 - 11:20AM
Business Wire
KCAS Bio continues to expand its global reach and has
selected Crux Biolabs (Melbourne, Australia) as its partner in
providing harmonized spectral flow cytometry across the US, Europe,
and Australia. The alliance enables KCAS Bio and Crux Biolabs to
support the global needs of clinical research by offering advanced
spectral flow cytometry using the Cytek Aurora platform. Crux
Biolabs is expected to be the first CRO in Australia to offer
spectral flow cytometry accredited for clinical research. Together,
the partnership is focused on being the global provider of choice
for outsourced flow cytometry clinical research.
KCAS Bio continues to deliver against both growth objectives and
more integrated customer service offerings. KCAS Bio has partnered
with Crux Biolabs, a leading provider of flow cytometry and
bioanalytical services located in Melbourne, Australia. KCAS Bio is
a leading international Contract Research Organization (CRO)
providing comprehensive GLP-compliant bioanalytical and biomarker
development testing services for the biotech, pharmaceutical, and
cell/gene therapy industries. KCAS Bio offers a complete range of
bioanalytical services from early discovery support through
registration, providing expertise in biological (large molecule),
synthetic (small molecule), and cell/gene therapy drug candidates.
KCAS Bio provides services from its three locations in Kansas City,
KS; the greater Philadelphia, PA, region; and Lyon, France.
John Bucksath, CEO of KCAS Bio, commented, “We are
delighted to partner with the Crux Biolabs team, working to
accelerate our combined offering of global development support to
the industries and customers we serve. We are committed to
supporting the partnership beyond just flow cytometry and are
actively engaging on next steps in the partnership. KCAS Bio has
embarked on significant investments in spectral flow cytometry,
including the placement of harmonized Cytek Aurora cytometers at
Crux Biolabs. We remain committed to attracting the industry’s top
scientific talent, focusing on outstanding customer service, and
accelerating global reach through additional acquisitions and
partnerships. With our investor, Vitruvian Partners, we are
optimally positioned to invest in our people and deliver
world-class services for our growing client base. The partnership
with Crux Biolabs enables our combined clients access to expanded
operational expertise and geographical reach, supporting the
increasing R&D needs of the industries we serve.”
Stefan Cross, CEO of Crux Biolabs, commented, “We are
excited about this partnership with KCAS Bio and our combined
ability to provide best-in-class services for the biopharma and
pharmaceutical industries. As a full-service bioanalytical CRO in
Australia, Crux Biolabs is well-positioned to support sponsors and
clients through the clinical trial journey – from pre-clinical
through full clinical development. Australia is well known for its
advantageous Phase 1 clinical trial capabilities and this alliance
will allow clients to develop flow cytometry assays for use
throughout the clinical trial lifecycle. Establishing common
practices and using a harmonized Cytek Aurora platform for spectral
flow cytometry with KCAS Bio will bring a unique and
industry-leading offering to our current and emerging clients.”
Further information:
About KCAS Bio – KCAS Bio is a premier international
provider of bioanalytical and laboratory services that provides
comprehensive GLP- and GCP-compliant development services from
early discovery support through commercial approval and beyond. One
of only a select few CROs offering both large and small molecule
development with extensive capabilities and expertise, KCAS Bio
provides a truly differentiated approach to its clients who are
looking for both scientific expertise and excellent customer
service. KCAS Bio is headquartered in Olathe, Kansas – the Kansas
City, KS metro area, supported by more than 360 employees. Further
information can be found at www.KCASBio.com.
Vitruvian Partners – a leading international growth
investor headquartered in London, with offices in Miami, San
Francisco, Madrid, Munich, Luxembourg, Mumbai, Singapore, and
Shanghai, and c$20bn of active funds. Vitruvian acquired KCAS Bio
in April 2021 and has supported the international expansion of the
business. Further information can be found at
www.vitruvianpartners.com.
About Crux Biolabs – Crux Biolabs, an Australian
bioanalytical laboratory, offers a wide range of GCLP/GCP-compliant
services. These services encompass PBMC processing,
pharmacodynamics (including biomarker, flow cytometry, ELISpot, and
anti-drug antibody assays), and pharmacokinetics for both large and
small molecules, all tailored to support clinical research. Our
team of highly skilled scientists, based in our ISO/IEC
17025-accredited lab in Melbourne, Victoria, specialize in the
development and validation of various biomarker and cell assays. We
also offer select services from our Sydney, New South Wales,
laboratory. For more information, please visit our website at
www.cruxbiolabs.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240503665774/en/
KCAS Bio Jeff Goddard, +1 317-626-0631
Jeff.Goddard@KCASBio.com
Crux Biolabs Stefan Cross, +61 3 9763 0110
stefan.cross@cruxbiolabs.com